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Background: Therapeutic targeting of the androgen signaling pathway is a mainstay treatment for prostate cancer.
Although initially effective, resistance to androgen targeted therapies develops followed by disease progression to
castrate-resistant prostate cancer (CRPC). Hypoxia and HIF1a have been implicated in the development of resistance
to androgen targeted therapies and progression to CRCP. The interplay between the androgen and hypoxia/HIF1a
signaling axes was investigated.
Methods: In vitro stable expression of HIF1a was established in the LNCaP cell line by physiological induction or
retroviral transduction. Tumor xenografts with stable expression of HIF1a were established in castrated and non-
castrated mouse models. Gene expression analysis identified transcriptional changes in response to androgen
treatment, hypoxia and HIF1a. The binding sites of the AR and HIF transcription factors were identified using ChIP-
seq.
Results: Androgen and HIF1a signaling promoted proliferation in vitro and enhanced tumor growth in vivo. The
stable expression of HIF1a in vivo restored tumor growth in the absence of endogenous androgens. Hypoxia
reduced AR binding sites whereas HIF binding sites were increased with androgen treatment under hypoxia. Gene
expression analysis identified seven genes that were upregulated both by AR and HIF1a, of which six were
prognostic.
Conclusions: The oncogenic AR, hypoxia and HIF1a pathways support prostate cancer development through
independent signaling pathways and transcriptomic profiles. AR and hypoxia/HIF1a signaling pathways
independently promote prostate cancer progression and therapeutic targeting of both pathways simultaneously is
warranted.
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Androgen signaling drives prostate cancer development
and progression. Endogenous androgens, testosterone
and dihydrotestosterone, bind to the intracellular andro-
gen receptor (AR) which translocates to the nucleus.
The AR functions as a transcription factor and activates
downstream signaling pathways associated with prolifer-
ation, invasion and metabolism [1]. Androgen
deprivation therapy (ADT) inhibits AR signaling by
blocking the production of androgens or by inhibiting
androgen binding to the AR. ADT is used to treat local-
ized, locally advanced and metastatic disease and an esti-
mated 50% of prostate cancer patients receive ADT [2].
Although ADT is initially effective, resistance subse-
quently develops and the AR signaling pathway remains
active even in the absence of endogenous androgens.
The development of androgen independent or castrate-
resistant prostate cancer (CRPC) is associated with the
presence of metastases and a rapid clinical demise [3].
Identifying which patients will progress to CRPC is a
major challenge in the treatment of prostate cancer. Un-
derstanding the biology that underpins progression to
CRPC will support the development of novel strategies
to identify, prevent and treat CRPC.
AR activity during CRPC can be sustained through a
number of alterations in the expression of the AR, in sig-
naling pathways and in the expression and activity of
other transcription factors which can interact with the
AR [4]. One of the earliest examples of these changes
was the identification of significant X chromosome copy
number amplification encompassing the AR gene locus
in a significant percentage of CRPC cases [5]. This was
associated with AR overexpression and believed to con-
tribute to androgen hypersensitivity. More recently AR
splice variants have been reported to be expressed in
CRPC which lack the ligand binding domain and display
constitutive transcriptional activity and regulate the ex-
pression of an altered repertoire of target genes [6]. Re-
searchers working on signaling pathways have identified
AR phosphorylation sites for Akt and other important
kinases functional downstream of receptor tyrosine ki-
nases [7]. These sites are also thought to maintain AR
transcriptional activity under conditions of androgen
deprivation. The AR has also been shown by us and
others to interact with a range of other transcription fac-
tors capable of recruiting into chromatin-associated
transcriptional complexes under conditions of androgen
deprivation. These include a number of ETS family tran-
scription factors amongst which we have identified ETS1
[8] and GABPA [9] and others have reported interac-
tions with ERG and ETV1 [10–12]. Such interactions are
believed to alter the identity of AR binding sites across
the genome and consequently also the identity of genes
that are regulated by AR recruitment to the genome. Itis possible that this is also the basis for effects of the
hypoxia inducible factor (HIF) pathway on the AR [13].
HIF is a heterodimer, consisting of a constitutively stable
HIF1b and a tightly regulated HIF1a subunit. Under oxy-
genated conditions, the HIF1a protein is ubiquitinated
and rapidly degraded. In the absence of oxygen, HIF1a is
stabilized and dimerizes with HIF1b subunits to form an
active HIF transcription complex. HIF translocates to
the nucleus and induces the expression of genes associ-
ated with metabolism, angiogenesis, invasion and cell
survival. Hypoxia-independent stabilization can also
occur– a condition referred to as pseudohypoxia [14]
[15]. Expression of HIF is associated with increased risk
and a poor prognosis in prostate cancer [16, 17].
Crosstalk between the AR and hypoxia/HIF has been
reported. ADT in hypoxia promotes adaptive androgen/
AR-independence, and confers resistance to androgen/
AR-targeted therapy [18] . Co-immunoprecipitation as-
says have confirmed a direct interaction between AR
and HIF1a, and ChIP analysis showed HIF1a interacts
with the AR on the PSA gene promoter [19]. Hypoxia
induced activation of HIF can also increase expression
of the AR [20, 21]. As AR and HIF signaling pathways
are major signaling hubs and oncogenic drivers of pros-
tate cancer progression, this study aimed to investigate
further the relationship between them. Here we report
for the first time that combined AR and HIF1a signaling
in vivo promotes tumor growth and demonstrate the
capacity of HIF1a to promote tumor growth in the ab-
sence of endogenous androgen in vivo. We also show
that the AR and HIF/hypoxia signaling pathways func-
tion independently regulating the transcription of differ-
ent subsets of genes with few shared targets.
Methods
Cell culture
LNCaP, LNCaP-Bic, LNCap-OHF and PC3 cell lines
(and the corresponding stable transfectants) were cul-
tured in RPMI with glutamine and 10% fetal calf serum.
LNCaP and PC3 cell-lines were procured from the
ATCC repository. LNCaP-Bic and LNCaP-OHF cell-
lines were derived through long term culture in bicaluta-
mide and hydroxyflutamide and were provided by Prof.
Zoran Culig (Medical University Innsbruck, Austria).
For hypoxia experiments, cells were exposed to 1% oxy-
gen using either a hypoxic workstation (INVIVO2, Rus-
kinn, Leeds, UK) or a hypoxic incubator. For AR
signaling experiments, LNCaP cells were grown in char-
coal stripped serum for 96 h prior to adding synthetic
androgen (R1881) or vehicle control (ethanol). All cell-
lines were authenticated by STR Profiling using the
ATCC Authentication Service and were subjected to
PCR-based mycoplasma testing every 2 weeks through-
out the course of the study with negative results
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derivation and propagation of any of the cell-lines used
in this study.
Infection of HIF1a retroviral vectors
A model of pseudohypoxia was established in androgen-
sensitive LNCaP cells by viral transfection of a vector
encoding HIF1a with two amino acid substitutions
which prevented its degradation in the presence of oxy-
gen. Viral supernatants were prepared by transfecting the
Phoenix packaging cell line (Orbigen, San Diego, CA)
using Lipofectamine 2000 (Life Technologies, Paisley,
UK). After initial transfection, Phoenix cells were grown
at 32 °C. The supernatant was collected and filtered
(0.45 μm), then supplemented with a 1:4 volume of fresh
medium with 7.5 μg/mL Polybrene (Sigma, Poole, UK),
and added to LNCaP cells plated on p100 dishes at 30–
40% confluence. After 20 h, cells were washed, and fresh
media added for 20 h before a second round of transfec-
tion and G418 selection. The constitutively active form of
HIF1a (carrying two substitutions: P402A and P564A) was
cloned into pBMN-I-EGFP.
Western blot analysis
Cell lysis involved urea-SDS buffer supplemented with
phenylmethylsulfonyl fluoride (PMSF) as previously de-
scribed [1]. Immunoblots were visualized with enhanced
chemiluminescence reagent or enhanced chemilumines-
cence plus reagent (Amersham, Arlington Heights, IL).
Antibodies used were HIF1a (clone 54, Transduction
Labs, Lexington KY) and α tubulin (CRUK).
Xenograft experiments
Xenograft tumors were generated with LNCaP/Empty
and LNCaP/HIF1-clone 1 cells that stably expressed a
fusion protein of luciferase and yellow fluorescent pro-
tein (YFP). There were four groups (Full/non-castrated
+ LNCaP/Empty, Full/non-castrated + LNCaP/HIF1a
clone 1, Castrated + LNCaP/Empty and Castrated +
LNCaP/HIF1a clone 1), each consisting of five mice.
Tumor growth was monitored weekly through biolumin-
escence with an IVIS camera (Xenogen) [1].
Clinical material and immunohistochemistry
Clinical samples were collected from Cambridge Univer-
sity Hospitals NHS Trust as part of the PROMPT study,
and ethical approval was granted by the local research
and ethics committee (LREC number: 02/281M) and by
the multicenter research and ethics committee (MREC
number 01/4061). A tissue microarray (TMA) was con-
structed, consisting of at least two tumor cores with
matched benign prostate tissue cores from each of 41
patients with CRPC. Sections 3 μm thick were mounted
on Snowcoat X-tra slides (Surgipath, Richmond, IL),dewaxed in xylene and rehydrated using graded ethanol
washes. For antigen retrieval, sections were immersed in
preheated DAKO target retrieval solution and treated
for 90 s in a pressure cooker (DAKO, Glostrup,
Denmark). Antigen/antibody complexes were detected
using the DAKO catalyzed signal amplification (CSA)
system according to the manufacturer’s instructions.
Sections were counterstained with hematoxylin for 30 s,
dehydrated in graded ethanol washes and mounted
(Lamb, London, UK). A rabbit pAb was used for HIF1a
immunohistochemistry in the xenograft tumors (#NB
100–479, Novus Biologicals, Oxford, UK) and a mouse
mAb was used for HIF1a immunohistochemistry in the
CR-TMA (H1α67 # NB 100–105, Novus Biologicals).
Immunohistochemistry staining was scored by two inde-
pendent blinded assessors as 1 (negative), 2 (< 25% of
nuclei staining), 3 (25–50% of nuclei staining), 4 (major-
ity of cells – weak staining), 5 (majority of cells – mod-
erate staining) and 6 (majority of cells – strong staining).
Illumina HumanWG v2 BeadArray data analysis
LNCaP, LNCaP/Empty and LNCaP/HIF1a clone 1 cells
were grown in charcoal stripped serum for 96 h prior to
adding 1 nM R1881 or 0.01% ethanol (vehicle control)
for 4 h and extracting RNA. Total RNA was extracted
using Trizol and isopropanol precipitation, according to
the manufacturers’ instructions. Quality control was per-
formed with an Agilent Bioanalyser. cRNA was gener-
ated and biotin labelled using the Illumina TotalPrep
RNA Amplification Kit, according to the manufacturers’
instructions. 250 ng of RNA was hybridized per sample
in accordance with the manufacturers’ instructions and
the literature [22]. Scanning was performed using Stand-
ard Illumina protocols.
For hypoxia experiments, LNCaP cells were exposed
to 1% hypoxia or normoxia for 24 h prior to RNA ex-
traction. Gene expression data were generated using the
Illumina HumanWGv2 BeadArrays. After background
correction, normalization and log2 transformation, dif-
ferential expression analysis was performed with
LIMMA on probe set level. Probe sets with bad and no
match probe scores were omitted from analysis. False
discovery rate adjusted P value of 0.05 and 1.5 fold
change were applied as cut-off.
Chromatin Immunoprecipitation
ChIP and re-ChIP was performed as previously de-
scribed [8, 23]. Cells were cultured in phenol red-free
RPMI media supplemented with 10% charcoal dextran-
stripped FBS for 72 h before adding 1 nM R1881 or
0.01% ethanol for 4 h. For hypoxic experiments, cells
were placed in a hypoxic incubator at 1% oxygen for 12
h prior to adding R1881 or ethanol. AR (AR N20, Sc-
816X, Santa Cruz), HIF1a (ab2185, Abcam), H3K4me1
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050, Diagenode, Seraing, Belgium) antibodies were used
in the assay. ChIP enrichment was tested by real-time
PCR and the remainder was used for single-end
SOLEXA library preparation.
ChIP-seq SOLEXA library preparation
Single-end SOLEXA sequencing libraries were prepared
as previously described [23]. Sequence reads were gener-
ated using an Illumina Genome Analyzer II and mapped
to the reference human genome before peak calling.
Called peaks were analysed in R using ChIPpeakAnno
package [24].
Data deposition
Microarray and ChIP-seq data generated have been
deposited within the National Center for Biotechnology
Information (NCBI) Gene Expression Omnibus (GEO)
database (https://www.ncbi.nlm.nih.gov/geo/) under
GSE114734.
Patient cohorts, endpoints and statistical analysis.
Five prostate cancer gene expression cohorts with pub-
lically available patient survival data were used to evalu-
ate the prognostic significance of selected genes: TCGA
[25], Taylor et al. GSE21032 [26], Long et al. GSE54460Fig. 1 HIF1a overexpression in the androgen dependent LNCaP cell line in
a, stable HIF1a expression increased cell proliferation compared to the LNC
vehicle control or synthetic androgen R1881 (two way multiple comparison
resistance to bicalutamide treatment (two-tail t-test, * p = 0.058). Data poin
± SEM. Differences in growth rates are due to cells grown in media contain
to treatment (a) or in standard RPMI median with FBS that contains androg[27], Ross-Adams et al. GSE70770 [25] and Sboner et al.
GSE16560 [28] (Supplementary Table 1). For TCGA,
GSE54460, GSE70770, GSE16560 gene expression data
were downloaded directly. For GSE21032, raw CEL files
were downloaded and processed using aroma package.
Biochemical recurrence-free (BCR) survival was the
primary endpoint, except for Sboner where only overall
survival was available. Patients were stratified into high
and low risk groups based on cohort median expression
of the gene of interest. Survival estimates were per-
formed using the Kaplan-Meier method. The log-rank
test was used to test the null hypothesis of equality of
survival distributions. Hazard ratios (HR) and 95% confi-
dence intervals (CI) were obtained using the Cox pro-
portional hazard model.Results
HIF1a expression promotes proliferation and resistance to
ADT in vitro and in vivo
The stable overexpression of HIF1a in LNCaP/HIF1a
clone 1 and clone 2 (Supplementary Fig. 1A) cells in-
creased proliferation and resistance to ADT (bicaluta-
mide) in vitro (Fig. 1). Growth rate decreased in
response to ADT in LNCaP/Empty but not LNCaP/creased proliferation and resistance to androgen deprivation therapy.
aP/Empty control cells when cells were treated with the ethanol
ANOVA; *p < 0.05, **p < 0.01). b, stable HIF1a expression led to
ts represent the mean of three intra-assay and two biological repeats
ing charcoal stripped serum (androgen depleted media) for 96 h prior
en and growth stimulants (b)
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moxia in ADT resistant (LNCaP-Bic, LNCaP-OHF) and
androgen-independent (PC3) cells but not in androgen
sensitive (LNCaP) cells (Supplementary Fig. 1). LNCaP/
HIF1a xenografts grew faster than the LNCaP/Empty tu-
mors, and were resistant to ADT (castrated mouse
model; Fig. 2).
Castrate resistant prostate cancers have high HIF1a
expression
HIF1a immunohistochemistry showed high levels of
HIF1a expression in CRPC. All CRPC biopsies expressed
HIF1a in comparison with only 57% of benign tumors.
Sixty-eight percent of CRPC biopsies had strong HIF1a
staining compared with just 8% of benign tissue (Supple-
mentary Fig. 2).
Only seven genes upregulated by both androgen and
HIF1a
In LNCaP cells, gene expression analysis identified 336
genes upregulated in response to synthetic androgen
(Supplementary Table 2) and 579 genes in response to
hypoxia (Supplementary Table 3). Forty-seven genes
were upregulated by both androgen and hypoxia (Fig. 3a).Fig. 2 HIF1a accelerated tumor growth in non-castrated (full) and castrated
line showed accelerated growth in full and castrated mice however LNCaP
compared to the full mouse model. In the castrated mice LNCaP/HIF1a tum
points represent the mean ± SEM, two-way ANOVA; **p < 0.01)There were 149 genes upregulated in response to syn-
thetic androgen in LNCaP/Empty cells and 56 genes up-
regulated in response to stable HIF1a expression (Fig. 3b).
Only seven genes (TWIST1, KCNN2, PPFIBP2, JAG1,
SPRED1, IGFBP3, NDRG1) were upregulated by both an-
drogen and HIF1a (Fig. 3b). Three genes (SPRED1,
IGFBP3, NDRG1) were upregulated by androgen, hypoxia
and stable HIF1a expression.
AR and HIF transcription factor binding sites increase
differently in response to androgen and hypoxia,
respectively
ChIP-seq analysis identified global AR and HIF DNA
binding sites in LNCaP cells exposed to synthetic andro-
gen under normoxia and hypoxia. There were more AR
(called peaks range 18,404 to 70,064) compared to HIF
(range 523 to 5795) transcription factor binding sites
(Table 1). The number of AR binding sites increased
with androgen treatment and decreased in hypoxia.
However, while hypoxia almost halved the number of
AR binding sites, they increased when androgen was
added under hypoxia (from 18,404 to 45,635) suggesting
an interplay between hypoxia and androgen signalling at
the level of AR recruitment to chromatin. AR bindingmice. A, tumor xenografts derived from the LNCaP/HIF1a clone 1 cell
/HIF1a tumors grew significantly slower in the castrated mouse
ors continued to grow whilst the empty control clone regressed (data
Fig. 3 Genes upregulated by androgen (R1881), hypoxia and HIF1a in LNCaP cells. a, 47 genes upregulated by androgen (LNCaP vehicle control
vs. LNCaP R1881, right circle) were independently upregulated by hypoxia (LNCaP normoxia vs. LNCaP 1% hypoxia, left circle). b, 7 genes
upregulated by HIF1a overexpression (LNCaP Empty vs. LNCaP HIF1a, left circle) were also independently upregulated by androgen (LNCaP Empty
vehicle control vs. LNCaP Empty R1881, right circle). Three genes were independently upregulated by and androgen, hypoxia and HIF1a (SPRED1,
NDRG1 and IGFBP)
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and androgen treated cells exposed to normoxia (86%)
and hypoxia (79%) (Fig. 4a). As expected hypoxia in-
creased the number of HIF binding sites, the greatest
number of HIF binding sites was observed in cell treated
with combined hypoxia and androgen treatment (Table
I). HIF binding sites were not conserved in cells between
normoxia and hypoxia in the absence (6%) or presence
(3%) of androgen (Fig. 4b). These experiments show an-
drogen increases the number of AR binding sites while
conserving those present in the absence of androgen, i.e.
AR binds to additional sites. In contrast, hypoxia in-
creases the number of HIF binding sites but with little
conservation, i.e. HIF binds to different sites in hypoxia.
These observations highlight differences in the effect on
transcription when the AR responds to androgen and
HIF to hypoxia.
Not all binding sites reflect sites of transcriptional ac-
tivity. A comparison with histone marks can refine this
landscape and help to identify those sites most likely tobe active: H3K4me1 is enriched at active and primed en-
hancers and H3K4me3 in a promoter (i.e. most likely to
be active) and stable H3K4me3 has been associated with
transcription initiation [29, 30]. Table 1 shows androgen
globally decreased both histone markers. In comparison,
hypoxia globally increased the number of histone marker
binding sites. Figure 5 A-D shows no change in the dis-
tribution of H3K4me1 in response or androgen or hyp-
oxia. Figure 5 E-H shows an increase in the percentage
of H3K4me3 located within promoter regions in re-
sponse to androgen and a decrease in response to hyp-
oxia. These observations are consistent with androgen
increasing and hypoxia decreasing transcription initi-
ation at transcriptional start sites.
The locations of the transcription factors (AR, HIF)
and the histone markers (H3K4me1, and H3K4me3)
were analysed within the exons and introns of the seven
genes identified in the gene expression analysis (Supple-
mentary Fig. 3). Neither AR nor HIF bound within the
TWIST1 and IGFBP3 genes (data not shown). There
Table 1 ChIP-seq global called peaks for AR, HIF and histone
methylation markers
Antibody Condition Called peaks
AR R1881/Normoxia 70,064
AR R1881/Hypoxia 45,635
AR Ethanol/Normoxia 35,320
AR Ethanol/Hypoxia 18,404
HIF R1881/Normoxia 523
HIF R1881/Hypoxia 5795
HIF Ethanol/Normoxia 1181
HIF Ethanol/Hypoxia 1746
H3K4Me1 R1881/Normoxia 74,269
H3K4Me1 R1881/Hypoxia 79,415
H3K4Me1 Ethanol/Normoxia 90,818
H3K4Me1 Ethanol/Hypoxia 95,424
H3K4Me3 R1881/Normoxia 16,419
H3K4Me3 R1881/Hypoxia 18,627
H3K4Me3 Ethanol/Normoxia 24,358
H3K4Me3 Ethanol/Hypoxia 38,929
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sites in KCNN2 and PPFIBP2 compared to the other
genes (Table 2). These observations suggest that KCNN2
and PPFIBP2 are directly regulated by promoter prox-
imal and intragenic recruitment of the AR and HIF1
whereas TWIST1 and IGFBP3 may be enhancer regu-
lated. Indeed changes in IGFBP3 expression have been
shown to be affected by and to affect the expression of a
range of genes through long-range chromatin andFig. 4 Conservation of AR and HIF binding sites. a, The majority of AR bind
AR called peaks in the normoxic ethanol vehicle control 86% were conserv
peaks in the hypoxic ethanol vehicle control 79% were conserved in the h
not conserved upon hypoxic exposure. Of the 523 HIF called peaks in the
treated cells under (left). Of the 1181 HIF called peaks in the normoxic etha
control cells (right)interchromosomal interactions [31]. In addition,
TWIST1 is known to function as a transcriptional driver
of EMT. Consequently, although the number of genes
we have identified as co-ordinately regulated by the AR
and HIF1 is small in number their impact may be far-
reaching.
Effect of TWIST1, KCNN2, PPFIBP2, JAG1, SPRED1, IGFBP3
and NDRG1 on prognosis
Five publically available prostatectomy gene expression
cohorts were used to test the prognostic significance of
the seven genes upregulated by androgen, stable HIF1a
expression and hypoxia (Table 3). TWIST1 was the most
prognostic with high expression associated with poor a
prognosis in three cohorts. Five of the genes were prog-
nostic in a single cohort and SPRED1 had no prognostic
significance (Table 3). We further compared TWIST1 to
a recently published hypoxia-gene associated prognostic
signature for prostate cancer [32]. The 28-gene prognos-
tic signature was derived from the TCGA cohort, and
had a significant proportion of genes absent in Sboner
et al. cohort. In Taylor et al. both TWIST1 (HR 2.45,
95% CI 1.01–5.93, P = 0.047) and the 28-gene signature
(HR 4.48, 95% CI 1.67–12.04, P = 0.0030) retained prog-
nostic significance.
Discussion
Hypoxia and HIF1a signaling are widely regarded as
cause and consequence, but there is increasing evidence
of pseudohypoxia - the expression of HIF1a in normoxia
– in multiple cancers [33]. Our LNCaP/HIF1a clones
represent a model of pseudohypoxia. Stable HIF1aing sites were conserved following androgen treatment. Of the 35,320
ed in the normoxic R1881 treated cells (left). Of the 18,404 AR called
ypoxic androgen treated cells under (right). b, HIF binding sites were
normoxic androgen cells 3% were conserved in the hypoxic androgen
nol vehicle control 6% were conserved in the hypoxic ethanol vehicle
Fig. 5 The global genomic distribution of the histone markers, H3K4me1 and H3K4me3, in the LNCaP ChIP-seq analysis. The distribution of the
H3K4me1 marker did not change with androgen treatment or hypoxia (a-d). Hypoxia decreased H3K4me3 markers within promoter regions (e vs
g). Synthetic androgen R1881 increased the location of H3K4me3 markers within promoter regions under normoxia (e vs f) and hypoxia (g vs h)
Table 2 Numbers of binding sites of transcription factors and
histone markers in selected gene in LNCap cells
KCNN2 PPFIBP2 JAG1 SPRED1 NDRG1
AN-H-AR 4 9 1 1 0
AN-H-HIF 0 4 0 0 2
AN-H-ME1 13 25 2 2 6
AN-H-ME3 0 2 1 1 2
AN-N-AR 8 11 2 6 3
AN-N-HIF 1 0 0 0 0
AN-N-ME1 18 15 1 6 4
AN-N-ME3 1 3 1 2 1
ET-H-AR 1 7 1 0 0
ET-H-HIF 0 0 0 0 0
ET-H-ME1 15 19 2 0 5
ET-H-ME3 4 8 2 1 4
ET-N-AR 6 9 1 3 1
ET-N-HIF 0 0 0 0 0
ET-N-ME1 18 11 2 2 5
ET-N-ME3 4 5 1 1 1
AN, synthetic androgen (R1881) treatment; ET, ethanol vehicle control;
N, normoxia; H, hypoxia; AR = androgen receptor; ME1, H3K4me1;
ME3, H3K4me3
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synthetic androgen R1881, and promoted resistance to
ADT in vitro and in vivo. Hypoxia and HIF have already
been implicated in the development and progression of
CRPC [34, 35]. Hypoxia was shown to induce AR inde-
pendence and confer resistance to ADT through a meta-
bolic switch favoring glycolysis [18]. Pseudohypoxia has
also been linked to the metabolic switch from oxidative
phosphorylation to glycolysis [36]. Expression of HIF1a
in normoxia has been reported in androgen dependent
prostate cells and in this study we report expression of
HIF1a in cells resistant to ADT (LNCaP-Bic, LNCaP-
OHF) and in the androgen independent PC3 cell line 10 22.
This study adds to the evidence implicating hypoxia and
HIF1a in androgen independence, CRPC and ADT
resistance.
The high expression of HIF1a in CRPC further sup-
ports the role of HIF1a in aggressive, androgen
dependent prostate cancer. Whether the high expression
of HIF1a was associated with pseudohypoxia or hypoxia
could not be determined in this study. In future studies
the hypoxia marker pimonidazole alongside HIF1a
would provide a valuable insight into the contribution of
hypoxia and pseudohypoxia in CRPC.
Table 3 Prognostic significance of selected genes in prostate cancer cohorts
Swedish Cambridge Long Taylor TCGA
TWIST1 2.05
(1.30–3.22)
P = 0.0019
0.95
(0.39–2.35)
P = 0.917
1.46
(0.84–2.54)
P = 0.178
2.69
(1.11–6.49)
P = 0.028
1.72
(1.13–2.60)
P = 0.01
KCNN2 2.39
(1.51–3.79)
P = 0.000216
1.91
(0.75–4.86)
P = 0.17
1.52
(0.87–2.27)
P = 0.14
1.78
(0.78–4.08)
P = 0.17
0.84
(0.56–1.26)
P = 0.41
SPRED1 NA 0.90
(0.36–2.23)
P = 0.81
0.76
(0.44–1.32)
P = 0.33
0.96
(0.43–2.13)
P = 0.91
0.96
(0.64–1.44)
P = 0.85
PPFIBP2 NA 1.21
(0.49–3.02)
P = 0.68
1.73
(0.99–3.03)
P = 0.05
0.86
(0.38–1.92)
P = 0.70
0.76
(0.50–1.13)
P = 0.17
JAG1 1.36
(0.88–2.10)
P = 0.17
2.23
(0.85–5.88)
P = 0.10
2.293
(1.28–4.12)
P = 0.005
1.25
(0.56–2.80)
P = 0.59
1.30
(0.87–1.94)
P = 0.21
IGFBP3 1.00
(0.65–1.55)
P = 0.99
1.09
(0.44–2.68)
P = 0.86
1.56
(0.89–2.73)
P = 0.12
1.99
(0.85–4.66)
P = 0.11
2.07
(1.36–3.20)
P = 0.0008
NDRG1 2.28
(1.43–3.64)
P = 0.0005
1.43
(0.58–3.56)
P = 0.44
0.81
(0.47–1.41)
P = 0.45
0.78
(0.34–1.75)
P = 0.54
0.96
(0.64–1.43)
P = 0.82
BCR biochemical recurrence; OS overall survival; NA not applicable
Values are hazard ratios (95% confidence intervals). Cohorts were stratified by the median expression of each gene
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lated in common by AR, hypoxia, and HIF1a. The finding
suggests the signaling pathways act independently and
regulate the expression of different subsets of genes. Other
studies have reported both positive and negative crosstalk
between androgen/AR and hypoxia/HIF1a [18, 37, 38].
Globally there were substantially more AR binding sites
than HIF binding sites, demonstrating androgen signaling
dominance over HIF signaling in the prostate cancer cells
studied. Interestingly, hypoxia decreased the number of
AR binding sites. This observation contrasts with studies
showing hypoxia enhances AR activity [38–40]. The vari-
ability in concentration and duration of androgen treat-
ment and hypoxia across studies is most likely responsible
for the conflicting results. The observed decrease in an-
drogen binding sites under hypoxia in our study may be
explained by conformational changes in chromatin struc-
ture induced by 12 h exposure to 1% hypoxia, which may
restrict the accessibility of AR binding sites [41].
The locations of the AR DNA binding sites in the
ethanol vehicle control and R1881 treated cells were
highly conserved. The 2-fold increase in AR binding sites
with R1881 treatment added to the existing AR binding
sites that were occupied in the absence of R1881. In
comparison, the DNA binding sites occupied by HIF
under normoxia were located in different regions to the
HIF binding sites occupied under hypoxia, indicating
that HIF binds to different sites in the DNA and pro-
motes the expression of a different subset of genes under
pseudohypoxia and hypoxia. Histone marks associatedwith active transcription were globally decreased within
the DNA following synthetic androgen R1881 treatment.
In contrast hypoxia marginally increased the presence
the two histone marks, and it has previously been re-
ported that hypoxia rapidly increases histone methyla-
tion independently of HIF [42]. Despite decreasing the
prevalence of H3K4me3, the location of this histone
mark within promoter regions was increased as a result
of R1881 treatment and indicates enhanced transcrip-
tional activity.
We found few HIF transcription factor binding sites
within the introns and exons of the seven genes upregu-
lated by androgen and HIF1a suggesting the HIF regu-
lated expression of these genes is most likely driven by it
binding to distal sites [43]. The greatest number of AR
binding sites within the genes was observed with andro-
gen treatment under normoxia, with a reduction in the
number of AR binding sites under hypoxia. This de-
crease in AR binding sites under hypoxia was observed
globally, possibly as a result of hypoxia induced con-
formational changes in the DNA which restrict the ac-
cessibility of AR binding sites. This implies that the
functional relationship between the AR and HIF1a can-
not be defined based on physical interaction and coloca-
lization of these transcription factors at particular
binding sites in the genome, in contrast to some studies
on ETS factors. Instead there are potentially higher
order changes in chromatin conformation that could
permit independent distal sites occupied by these two
transcription factors to interact and perhaps interfere
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yond the scope of this study and will require chromo-
some conformation capture methods coupled to high-
throughput sequencing. It also is possible that many of
the HIF1a effects on AR binding are much more indirect
than this and reflect changes in i) intracellular signaling
and metabolism ii) concomitant epigenetic changes for
example in DNA methylation iii) changes in the expres-
sion and of other transcription factors which collectively
impact on AR recruitment and gene regulation. In-depth
dissection of each of these aspects awaits future studies
however it is intriguing that amongst the small number
of genes upregulated by both androgen and HIF one,
TWIST1, is a transcription factor and was the most
prognostic.
Upregulated TWIST1 and AR expression have previ-
ously been reported in a castration resistant LNCaP
mouse model, implicating crosstalk between epithelial
mesenchymal transition and castration resistance [44].
TWIST1 was also shown to upregulate AR expression
and to be upregulated in response to ADT [45]. The
variability in prognostic significance between the cohorts
may in part be due to use of different gene expression
platforms. A further limitation is that most patients in the
cohorts had primary prostate cancer treated by radical
prostatectomy without hormone therapy and were mostly
low and intermediate risk patients. Considering the seven
genes identified in this study are upregulated by androgen,
HIF1a and/or hypoxia it is hypothesized that they pro-
mote disease progression and development of CRPC and
it would be interesting to look at the expression of these
genes in high risk and advanced prostate cancer cohorts.
As AR and HIF signaling axes are active in CRPC these
seven genes are potential biomarkers of aggressive disease
that might be useful to predict likely disease progression
towards CRPC [46, 47].
Conclusion
In this study the absence of HIF1a and endogenous an-
drogen in vivo resulted in regression of tumor growth
but HIF1a signaling could restore tumor growth in the
absence of AR signaling. The data presented here indi-
cate simultaneous therapeutic inhibition of the HIF1a
and AR signaling pathways is a potential therapeutic
strategy, as has previously been proposed [47]. We show
that the oncogenic signaling pathways target the expres-
sion of different subsets of genes but both promote pro-
liferation, tumor growth and disease progression. The
relationship between the AR and HIF1a signaling path-
ways and their association with the development of
CRPC could be exploited to identify predictive bio-
markers of progression to CRPC and dual targeting of
the AR and hypoxia/HIF1a should be further investi-
gated for patients most at risk of developing CRPC.Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12885-020-06890-6.
Additional file 1.
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